enVVeno Medical Corp (NVNO) - Total Assets
Based on the latest financial reports, enVVeno Medical Corp (NVNO) holds total assets worth $32.35 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
enVVeno Medical Corp - Total Assets Trend (2014–2024)
This chart illustrates how enVVeno Medical Corp's total assets have evolved over time, based on quarterly financial data. Also see NVNO market cap for the company's overall valuation and market capitalisation.
enVVeno Medical Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
enVVeno Medical Corp's total assets of $32.35 Million consist of 97.3% current assets and 2.7% non-current assets. Review enVVeno Medical Corp total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how enVVeno Medical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NVNO stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: enVVeno Medical Corp's current assets represent 97.3% of total assets in 2024, an increase from 30.3% in 2014.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, up from 3.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 61.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
enVVeno Medical Corp Competitors by Total Assets
Key competitors of enVVeno Medical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
enVVeno Medical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.12 | 22.01 | 3.00 |
| Quick Ratio | 13.12 | 22.01 | 3.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.10 Million | $46.82 Million | $6.38 Million |
enVVeno Medical Corp - Advanced Valuation Insights
This section examines the relationship between enVVeno Medical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.21 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | $44.95 Million |
| Market Capitalization | $5.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values enVVeno Medical Corp's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: enVVeno Medical Corp's assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for enVVeno Medical Corp (2014–2024)
The table below shows the annual total assets of enVVeno Medical Corp from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $44.95 Million | -7.57% |
| 2023-12-31 | $48.63 Million | +16.74% |
| 2022-12-31 | $41.66 Million | -27.80% |
| 2021-12-31 | $57.70 Million | +447.54% |
| 2020-12-31 | $10.54 Million | +206.85% |
| 2019-12-31 | $3.43 Million | -3.52% |
| 2018-12-31 | $3.56 Million | +60.71% |
| 2017-12-31 | $2.21 Million | +24.23% |
| 2016-12-31 | $1.78 Million | -37.98% |
| 2015-12-31 | $2.87 Million | +79.95% |
| 2014-12-31 | $1.60 Million | -- |
About enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more